On cough syrups, a long overdue prescription

The Centre’s decision to remove cough syrups from Schedule K of the Drugs Rules, 1945 — the list of medicines that can be sold without a prescription — is a belated but necessary acknowledgement of a regulatory failure that has persisted for years and resulted in multiple tragedies. In October 2025, over 20 children died across Madhya Pradesh and Rajasthan after consuming locally procured cough syrups. Between December 2019 and January 2020, there were similar casualties in Jammu. These domestic disasters came on top of a scarred international record: India-made cough syrups have been tied to the deaths of more than 140 children in Africa and Central Asia since 2022.

Cough syrups occupy an anomalous position in India’s drug regulation framework. While recognised as medicines, many formulations — crucially those under Entry number 13 of Schedule K — benefitted from exemptions that enabled their sale through channels subject to weaker oversight than licensed pharmacies. This has fostered a culture of self-medication, poor prescription discipline and fragmented accountability across the supply chain. Particularly affected are vulnerable communities, especially in villages with a population of less than 1,000, where their sale was permitted — in MP, for instance, it was found that the cough syrup in question, Coldrif, contained diethylene glycol far in excess of permissible limits. The change in law translates to a shift in access. All syrup-based medicines, including cough syrups containing opioids like codeine, can no longer be purchased over the counter. Yet the prescription mandate, on its own, is unlikely to be sufficient. Drug regulation in India suffers from a Centre-state coordination deficit, and investigations after tragedies have repeatedly pointed to loopholes in quality control and inspection, raising uncomfortable questions about the capacity of regulators to monitor a rapidly expanding pharma sector. Concerns also remain about rural India, where limited access to healthcare facilities risks pushing people toward unlicensed vendors. The new rule must, therefore, be accompanied by rigorous enforcement, greater transparency in reporting adverse events, and investment in rural healthcare. The country must focus on a regulatory culture that prioritises patient safety over crisis management.

Overall Analysis

This editorial welcomes the Centre’s decision to remove cough syrups from Schedule K of the Drugs Rules, 1945, thereby ending their exemption from prescription requirements. The author argues that this move is long overdue and represents an acknowledgment of serious regulatory shortcomings that have contributed to repeated public health tragedies in India and abroad.

The editorial begins by highlighting the human cost of weak regulation. By referring to the deaths of children in Madhya Pradesh, Rajasthan, and Jammu, as well as fatalities linked to India-made cough syrups in Africa and Central Asia, the writer establishes the urgency of the issue. The use of real-life tragedies strengthens the argument that regulatory lapses are not merely administrative failures but matters of life and death.

The article then examines the structural problems within India’s drug regulation framework. It points out that cough syrups occupied a peculiar position in the law: although classified as medicines, certain formulations could be sold without prescriptions under Schedule K exemptions. According to the author, this created an environment that encouraged self-medication, weak oversight, and fragmented accountability. The editorial uses the example of contaminated syrup containing excessive levels of diethylene glycol to demonstrate how regulatory loopholes can lead to dangerous consequences.

However, the writer does not view the prescription mandate as a complete solution. The editorial argues that deeper issues persist, including weak coordination between central and state regulators, inadequate inspection mechanisms, and challenges in monitoring a rapidly growing pharmaceutical sector. It also raises concerns about rural areas, where limited healthcare access may push people toward informal or unlicensed sources of medicines.

The central message is that legal reform must be accompanied by stronger enforcement, better quality control, transparent reporting of adverse drug events, and improved healthcare infrastructure. The editorial ultimately advocates a shift from a reactive, crisis-driven approach to a preventive regulatory culture focused on patient safety.

Important Vocabulary (5)

1. Belated – occurring later than expected or desirable.
2. Anomalous – unusual or deviating from what is normal.
3. Exemptions – official permissions that free someone or something from a rule.
4. Fragmented – divided into separate and disconnected parts.
5. Loopholes – weaknesses or gaps in a law or system that allow rules to be bypassed.

Conclusion & Tone

The editorial argues that making cough syrups prescription-only is an important and necessary reform, but lasting improvement requires stronger regulatory oversight, stricter quality control, and better healthcare access. It stresses that patient safety should be the foundation of India’s pharmaceutical regulation rather than a response after tragedies occur.

Tone: Critical, analytical, and reform-oriented.